678P Real-world evidence of first-line cetuximab (CX) plus paclitaxel (PX) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Cirauqui, Beatriz; Trufero, Javier Martínez; Serrahima, M. Plana; Castaño, Adolfo; Rubió-Casadevall, J.; Maseda, Alberto Carral; Docampo, Lara Iglesias; Segura, Pedro Pérez; Lenza, Isaac Ceballos; Calderón, V. Gutiérrez; Salvá, Javier; Álvarez, C. Pena; Arrula, V. Arrazubi; Morillo, Elvira del Barco; Conde, Manuel; Martínez-Galán, Joaquina; Sánchez, M. Durán; Quiroga, V.; Ortega, E.; Nin, R. Mesia

doi:10.1016/j.annonc.2022.07.802

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the HANNA study showed that median OS was 25.6 months in patients with a PS score of 0 and 5.7 months in patients with a PS score > 2 ( 10 ). A phase 2 trial testing cetuximab plus weekly paclitaxel as first-line therapy for recurrent or metastatic HNSCC showed that median OS was 18.6 months in patients with a PS score of 0 and 7.3 months in patients with a PS score of 2 ( 11 ). These studies demonstrated that the PS score is an important prognostic factor, especially under anti-PD-1 monotherapy.…”

Section: Discussionmentioning

confidence: 99%

Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study

Wu,

An,

Zhong

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectivesThe efficacy of treatments targeting recurrent or metastatic head and neck squamous cell carcinoma are unsatisfactory in practice for patients with a ECOG PS score ≥ 2. Thus, this study retrospectively evaluated the safety and efficacy of a programmed cell death 1 inhibitor (tislelizumab) combined with an epidermal growth factor receptor inhibitor (nimotuzumab) in treating patients with a PS score ≥ 2 who suffer from recurrent or metastatic oral squamous cell carcinoma (OSCC).Materials and methodsFifteen patients were treated with tislelizumab (200 mg IV Q3W) and nimotuzumab (200 mg IV Q3W). Programmed cell death-ligand 1 (PD-L1) expression in tumor biopsies was assessed with immunohistochemistry. Whole-exome sequencing was used to evaluate treatment efficacy based on PD-L1 expression and gene mutation.ResultsAt a median follow-up of 9.6 months, median overall survival was 10.1 months, and median progression-free survival was 4.0 months. Overall response rate was 40%, with 6/15 patients achieving partial response. Eight patients exhibited nine adverse events, eight out of nine being grade 2 and the remaining being grade 3. Whole-exome sequencing showed that DYNC1I2, THSD7A, and FAT1 mutations were associated with patient prognosis.ConclusionCombination therapy involving tislelizumab plus nimotuzumab is a promising, low-toxicity treatment for recurrent or metastatic OSCC in patients with a PS score ≥ 2.

show abstract

Section: Discussionmentioning

confidence: 99%